GS-7340/darunavir/cobicistat/emtricitabine: Phase II started

Gilead disclosed in its 2Q12 earnings that it began a double-blind, U.S. Phase II trial to compare a once-daily GS-7340/darunavir/cobicistat/emtricitabine vs. cobicistat-boosted Prezista darunavir plus Truvada emtricitabine/tenofovir in treatment-naïve patients with HIV-1 infection. GS-7340 is in Phase II testing for HIV infection while cobicistat, an inhibitor of cytochrome P450 family 3 subfamily A ( CYP3A), is in Phase III testing. Gilead markets Emtriva emtricitabine, a nucleoside analog reverse transcriptase inhibitor (NRTI) and Truvada, a fixed-dose combination of the NRTIs emtricitabine and tenofovir. Johnson & Johnson markets Prezista, a second-generation protease inhibitor. ...